Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

被引：0
|
作者：
Dong Ding
Huabin Hu
Mengting Liao
Yin Shi
Longjiang She
Linli Yao
Youwen Zhu
Shan Zeng
Jin Huang
机构：
[1] Xiangya Hospital,Department of Oncology
[2] Central South University,Department of Medical Oncology
[3] The Sixth Affiliated Hospital of Sun Yat-Sen University,Guangdong Institute of Gastroenterology
[4] Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases,Department of Health Management Center
[5] Xiangya Hospital,Department of Pharmacy
[6] Central South University,undefined
[7] Xiangya Hospital Central South University,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Atezolizumab; Cost-effectiveness; Non-small cell lung cancer; Oncology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2116 / 2126
页数：10
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Liao, Mengting
    Shi, Yin
    She, Longjiang
    Yao, Linli
    Zhu, Youwen
    Zeng, Shan
    Huang, Jin
    ADVANCES IN THERAPY, 2020, 37 (05) : 2116 - 2126
  • [2] First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
    Yang, Zhiguang
    Zhu, Yumei
    Xiang, Guiyuan
    Hua, Tiantian
    Ni, Jun
    Zhao, Jie
    Lu, Yun
    Wu, Yingyu
    Chang, Feng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1061 - 1067
  • [3] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China
    Liu, Huiqin
    Wang, Ying
    He, Qi
    HEALTH ECONOMICS REVIEW, 2022, 12 (01)
  • [6] Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China
    Jiang, Yuan
    Wang, Xingwei
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (03) : 139 - 144
  • [7] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE
    Chouaid, C.
    Bensimon, L.
    Millier, A.
    Clay, E.
    Insinga, R.
    Arunachalam, A.
    Khandelwal, A.
    Bachelot, Levy L.
    Levy, P.
    VALUE IN HEALTH, 2019, 22 : S458 - S458
  • [8] Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
    Huiqin Liu
    Ying Wang
    Qi He
    Health Economics Review, 12
  • [9] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB VS. PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF NON-SQUAMOUS, ADVANCED NON-SMALL CELL LUNG CANCER IN THE USA
    Chen, J.
    Velcheti, V.
    Padula, W.
    VALUE IN HEALTH, 2022, 25 (07) : S342 - S342
  • [10] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Rihua Cheng
    Zhen Zhou
    Qiao Liu
    Advances in Therapy, 2023, 40 : 4298 - 4309
12345